Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.
<h4>Background</h4>Type 2 diabetes is treated in a stepwise manner, progressing from diet and physical activity to oral antidiabetic agents and insulin. The oral agent pioglitazone is licensed for use with insulin when metformin is contraindicated or not tolerated. This systematic review...
Saved in:
Main Authors: | Christine Clar, Pamela Royle, Norman Waugh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-07-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0006112&type=printable |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin Regimens and Clinical Covariates among Type 2 Diabetes patients
by: Mahmoud Emad El-din Mohamed Abdalla1, et al.
Published: (2024-02-01) -
OPTIMAL REGIMENS OF THE BASAL-BOLUS INSULIN THERAPY IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
by: G. A. Galkina, et al.
Published: (2015-10-01) -
Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis.
by: Elizabeth S Mearns, et al.
Published: (2015-01-01) -
Pharmacokinetic Interaction of Favipiravir with Citalopram and Pioglitazone
by: Zeliha Keskin Alkaç, et al.
Published: (2022-12-01) -
Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment
by: S. К. Zyryanov, et al.
Published: (2025-02-01)